Schedule I barriers, the FDA drug development pipeline, promising clinical trials in PTSD and cancer pain, the international research landscape, and what the next decade looks like.
Cannabis is the most widely used illicit substance in the world and has been consumed by humans for thousands of years. Yet its scientific research base is strikingly thin compared to most pharmaceutical agents — there are fewer rigorous human clinical trials on cannabis than on many recently approved drugs that have been used for a fraction of the time. Understanding why this gap exists requires understanding the regulatory architecture that has surrounded cannabis research since the 1970 Controlled Substances Act.
The combination of Schedule I classification, DEA research registration requirements, the historical NIDA monopoly on research-grade cannabis supply, funding biases toward harm research, and the absence of pharmaceutical industry investment has created a research environment that is structurally resistant to generating the Phase 2 and Phase 3 trials that establish evidence-based therapeutic applications. The National Academies of Sciences, Engineering and Medicine’s comprehensive 2017 report on cannabis health effects — spanning nearly 500 pages — found the evidence base "limited," "moderate," or "substantial" across dozens of therapeutic and harm-related questions, but found the evidence sufficient to reach definitive conclusions on relatively few of them. The report explicitly identified research infrastructure barriers as a primary reason for the uncertainty.
A researcher at an American university who wants to study whether cannabis reduces chronic pain in human subjects faces a bureaucratic process with no equivalent for studying alcohol, caffeine, nicotine, or even opioid pharmaceuticals. The DEA Schedule I researcher registration requires a completed DEA-225 form, DEA site inspection of proposed secure storage facilities, institutional DEA registration, state-level permits where required, and a purchase order from an approved Schedule I source. Historically, the sole federally approved source was the NIDA Drug Supply Program at the University of Mississippi — the only licensed cultivator of research cannabis for decades.
The University of Mississippi supply was a source of ongoing scientific criticism. Cannabis grown for NIDA research was stored for years before distribution, resulting in low terpene content, significant cannabinoid degradation, and THC concentrations far below contemporary commercial products. Studies using NIDA cannabis were testing a product that bore little resemblance to what patients were actually consuming. The DEA approved its first additional cannabis cultivators for research in 2021 — a significant policy shift — but the transition to a diversified supply chain that reflects the actual product landscape is still ongoing.
The proposed reclassification of cannabis from Schedule I to Schedule III, following a 2024 Department of Health and Human Services recommendation, would represent the most significant structural change to US cannabis research policy in 50 years. Schedule III registration is a less burdensome process; Schedule III drugs do not require the DEA Controlled Substance Ordering System for researcher acquisition; and the stigma reduction — both institutional and in grant review panels — could meaningfully open funding pipelines.
Two cannabis-derived products have navigated the FDA’s full drug approval process: Epidiolex (cannabidiol) and dronabinol/nabilone (synthetic THC analogs). Their development trajectories illustrate both what is possible within the existing regulatory system and the specific challenges involved.
Epidiolex (GW Pharmaceuticals, now Jazz Pharmaceuticals) received FDA approval in June 2018 for Lennox-Gastaut syndrome and Dravet syndrome — two severe, treatment-resistant childhood epilepsy disorders. The development involved three Phase 3 randomized controlled trials enrolling over 500 patients total, conducted over approximately five years, at a cost estimated at hundreds of millions of dollars. GW was able to fund this development because CBD from a specific plant variety (Charlotte’s Web’s precursor genetics) could be patented in processed form, providing IP protection for the investment. Following Epidiolex’s approval, Phase 3 trials for CDKL5 deficiency disorder and tuberous sclerosis complex were also completed successfully, with approvals following.
The FDA drug development pathway for additional cannabis-derived drugs faces specific challenges beyond cost. Natural plant extracts are difficult to patent comprehensively, reducing pharmaceutical investment incentive. The complexity of plant-derived full-spectrum preparations creates characterization and batch consistency challenges that FDA chemistry, manufacturing, and controls (CMC) requirements demand be resolved before trials begin. And the FDA’s requirement for evidence of superiority over existing treatments — not just efficacy — sets a high bar in therapeutic areas where existing (often less expensive, less stigmatized) treatments have moderate efficacy.
| Therapeutic Area | Current Evidence Stage | Key Research | Timeline to Maturity |
|---|---|---|---|
| Epilepsy (rare syndromes) | FDA approved (Epidiolex) | Phase 3 RCTs completed for LGS, DS, TSC | Additional indications underway now |
| Cancer-related pain | Phase 3 (nabiximols) | GW Pharmaceuticals Phase 3 trials; multiple investigator-initiated trials | 3-6 years to potential US approval |
| PTSD | Phase 2 completed; Phase 3 needed | MAPS-supported research; VA-affiliated observational studies | 5-10 years; depends on federal policy change |
| Multiple Sclerosis spasticity | Approved outside US (Sativex) | Multiple European and Canadian Phase 3 trials complete | US approval potential within 5 years post-rescheduling |
| Inflammatory Bowel Disease | Phase 2 | CB1/CB2 receptor expression in gut; multiple Phase 2 trials showing signal | 7-12 years |
| Opioid use disorder | Phase 2; strong preclinical | CBD’s cue-induced craving reduction in human lab studies (Hurd et al., 2019) | 5-10 years |
| Alzheimer’s disease symptoms | Phase 2; preliminary | Agitation, BPSD symptom trials; neuroprotection preclinical | 10-15 years for definitive evidence |
Post-traumatic stress disorder is perhaps the clearest example of how Schedule I barriers have delayed research with potentially large public health impact. PTSD affects an estimated 12 million Americans in a given year, with veterans, sexual assault survivors, and first responders disproportionately affected. Existing pharmacological treatments (SSRIs, SNRIs, prazosin) have limited efficacy and substantial side effect burdens. Psychotherapy-based approaches are effective but inaccessible for many patients.
The biological rationale for cannabis in PTSD is compelling. PTSD involves dysfunction in fear extinction — the neural process of learning that a previously threatening stimulus is no longer dangerous. The endocannabinoid system, particularly CB1 receptors in the amygdala and prefrontal cortex, plays a central role in fear extinction. Studies in rodent PTSD models consistently show that endocannabinoid signaling facilitates extinction learning, while CB1 receptor blockade impairs it. PTSD patients have lower circulating anandamide concentrations than controls, and polymorphisms in fatty acid amide hydrolase (FAAH — the enzyme that degrades anandamide) affect PTSD vulnerability.
Multiple Phase 2 studies have shown signal for cannabis reducing PTSD symptom severity, but the DEA’s resistance to authorizing a fully powered Phase 3 trial — which would require large amounts of research-grade cannabis and extensive multi-site coordination — has prevented the evidence base from reaching FDA decision standards. Veteran advocacy organizations have been the most prominent voices calling for accelerated research.
While US research has been hampered by regulatory constraints, other countries have developed significant cannabis science infrastructure. Israel maintains the world’s highest per-capita cannabis publication rate and hosts the Endocannabinoid Research Group — a network of institutions studying the ECS across neurology, immunology, and oncology. The Hebrew University of Jerusalem’s Wolfson Centre for Drug Research directly descends from Mechoulam’s group and continues as a world center for cannabinoid pharmacology.
Canada’s federal legalization created research access that the US lacks — researchers can obtain standardized legal cannabis for clinical studies through Health Canada’s licensed producer framework, conduct consumer surveys with legal purchasers, and study real-world outcomes in a nationally documented cannabis use population. The Canadian Institutes of Health Research has funded cohort studies following legal cannabis users across multiple years — the kind of longitudinal data that would resolve many outstanding questions about long-term effects that the US cannot currently generate at scale.
Germany, which partially legalized cannabis for personal use in April 2024, has the largest European cannabis market and a highly developed clinical trial infrastructure. German research institutions have rapidly initiated trials in pain, sleep, and neurological applications that were previously impractical.
Beyond specific disease applications, the biggest opportunity in cannabis science is deeper understanding of the endocannabinoid system (ECS) itself. The ECS — comprising CB1 and CB2 receptors, endogenous cannabinoid ligands (anandamide, 2-AG), and the enzymes that synthesize and degrade them — is one of the most broadly distributed signaling systems in the human body. CB1 receptors are the most abundant G-protein coupled receptors in the brain. CB2 receptors are expressed throughout the immune system and, increasingly evidenced, in neurons as well.
The ECS regulates neuroplasticity, immune modulation, energy homeostasis, pain processing, mood, sleep, reproductive function, and cardiovascular function — essentially every major physiological system is touched by endocannabinoid signaling. Despite this, ECS research is estimated to receive a tiny fraction of the NIH funding directed at comparably important signaling systems like the opioid or serotonin systems.
A decade of unrestricted ECS research — the kind that would be enabled by schedule reclassification or federal legalization — represents one of the most significant opportunities in biomedical science. The therapeutic implications of precisely modulating endocannabinoid tone in specific tissues, using plant-derived cannabinoids or synthetic ECS-targeting drugs inspired by cannabis pharmacology, extend far beyond the current medical cannabis framework.
Schedule I creates multiple overlapping barriers: DEA researcher registration (historically taking 12-24 months), the historical NIDA monopoly on research-grade cannabis supply (which produced unrepresentative product), funding bias toward harm research over therapeutic research, and IP challenges that reduce pharmaceutical investment. The combination means researchers face more bureaucracy, less money, lower-quality study material, and less institutional support than for research on most other substances.
Leading areas: cancer pain (nabiximols Phase 3 trials with GW/Jazz Pharmaceuticals); PTSD (Phase 2 completed, Phase 3 blocked by policy); epilepsy (ongoing expansion of Epidiolex indications); MS spasticity (Sativex — approved outside US, US trials in planning); opioid use disorder (CBD cue-craving reduction, Hurd et al.); and IBD/Crohn’s disease (multiple Phase 2 trials showing signal).
Schedule III would reduce registration burdens (faster DEA approval, less stringent storage requirements), reduce institutional stigma at universities, potentially ease NIH grant review, and allow pharmaceutical companies to pursue research with less regulatory friction. It would not fully resolve NIDA supply issues, FDA approval pathway challenges for plant-derived extracts, or state-level restrictions. It is a meaningful improvement, not a complete solution. Full federal legalization or descheduling would have the largest research impact.
Israel leads per capita — Mechoulam’s legacy and a research-permissive regulatory environment since the 1960s. Canada provides the most accessible legal research framework since 2018 legalization. The Netherlands has operated a pharmaceutical cannabis supply program for European researchers for decades. Germany became the largest European market in 2024, accelerating trial activity. Australia has been progressive in pain and chronic illness cannabis research since 2016. All of these countries produce research that US investigators currently cannot conduct at equivalent scale.